BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23

• 

  Opinion

  How Abogen went from COVID hype to a $7.8B Novartis deal

  After Abogen Biosciences’ COVID shot missed the commercial window, the big question was whether its mRNA technology could create value beyond vaccines. Novartis’ $575 million upfront commitment is the clearest external validation yet of that broader therapeutic potential.

  October 9, 2026

   · 

  5 min read

   · 

  Lewis Zhang
• Press Releases

  FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

  October 9, 2026

   · 

  7 min read
• Press Releases

  FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer

  October 9, 2026

   · 

  16 min read
• Press Releases

  Ascensia Announces Strategic Partnership with Sava for Innovative Microsensor Technology

  October 9, 2026

   · 

  4 min read
• Press Releases

  Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

  October 9, 2026

   · 

  10 min read
• Press Releases

  A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura’s roginolisib

  October 9, 2026

   · 

  7 min read
• Press Releases

  MIDEA COMPLETES THE ACQUISITION OF ESAOTE

  October 9, 2026

   · 

  3 min read
• 

  Deals

  Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business

  With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.

  October 9, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• Press Releases

  Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis’ Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

  October 9, 2026

   · 

  9 min read
• Press Releases

  Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference

  October 9, 2026

   · 

  1 min read